Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 20/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18917208 | 0.92 | ELANE (0.54) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2742382 | 0.89 | ELANE (0.71) | ELANECYP2C9CYP3A4 | |
| SCHEMBL12329665 | 0.87 | ELANE (0.69) | ELANECYP2C9CYP3A4 | |
| SCHEMBL12330070 | 0.87 | ELANE (0.65) | ELANECYP2C9CYP3A4 | |
| SCHEMBL14937514 | 0.86 | ELANE (0.63) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2742383 | 0.85 | ELANE (0.72) | ELANECYP2C9CYP3A4 | |
| SCHEMBL230667 | 0.84 | ELANE (0.70) | ELANECYP2C9CYP3A4 | |
| SCHEMBL2742384 | 0.83 | ELANE (0.69) | ELANECYP2C9CYP3A4 | |
| SCHEMBL233309 | 0.83 | ELANE (0.67) | ELANECYP2C9CYP3A4 | |
| SCHEMBL230939 | 0.82 | ELANE (0.66) | ELANECYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545057-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD | CHIESI FARM SPA (IT) | 2017-06-07 | — | — | EP | disclosed |
| US-9120802-B2 | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-01 | — | — | US | disclosed |
| US-9120802-B2 | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-01 | — | — | US | disclosed |
| US-9120802-B2 | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-09-01 | — | — | US | disclosed |
| US-20130123278-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123278-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123278-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-16 | — | — | US | disclosed |
| WO-2011110859-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123278-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISEASES SUCH AS COPD | XDH, SERPINB1, CCR9 | ELANE 10/4885CYP2C9 15/4885CYP3A4 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.